Immunic AG has disclosed deuterated dihydroorotate dehydrogenase (DHODH) inhibitors reported to be useful for the treatment of Crohn's disease, influenza, lupus erythematosus, multiple sclerosis, psoriasis, rheumatoid arthritis, SARS-CoV-2 infection (COVID-19) and cancer.

Sumitomo Pharma Co. Ltd. has divulged bicyclic pyridine derivatives acting as trace amine-associated receptor 1 (TAAR1) agonists reported to be useful for the treatment of neurological and psychiatric disorders.

Hainan Sparkle Therapeutics Co. Ltd. has described ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.

Shandong Luye Pharmaceutical Co. Ltd. has divulged cannabidiol prodrugs reported to be useful for the treatment of cancer, tremor, epilepsy, anxiety disorder, inflammatory disorders, pain, multiple sclerosis and Parkinson's disease, among others.

Lifearc has identified pyrimidine compounds acting as serine/threonine-protein kinase ULK inhibitors reported to be useful for the treatment of chronic myeloid leukemia.

The University of Basel has synthesized triazine derivatives acting as phosphatidylinositol 3-kinase (PI3K) inhibitors reported to be useful for the treatment of cancer, neurological and immunological disorders.

Rhizen Pharmaceuticals SA and Incozen Therapeutics Pvt. Ltd. have disclosed salts of NAD+ ADP-ribosyltransferase poly [ADP-ribose] polymerase (PARP) inhibitors reported to be useful for the treatment of cancer, bone, cardiovascular, immunological, inflammatory and respiratory disorders, metabolic diseases and thrombosis.

Cosmas Therapeutics Development Inc. has discovered prodrugs of UCM-924 acting as melatonin MT2 receptor agonists reported to be useful for the treatment of pain, depression, diabetes, sleep and anxiety disorders.

Leitat Technological Center has patented sigma non-opioid intracellular receptor 1 (SIGMAR1) and/or sigma intracellular receptor 2 (TMEM97) ligands reported to be useful for the treatment of pain and neurological disorders.

Hangzhou Innogate Pharma Co. Ltd. has synthesized GTPase KRAS (Gly12Asp mutant) inhibitors reported to be useful for the treatment of cancer.